Karl Ziegelbauer

Summary

Affiliation: Bayer HealthCare AG
Country: Germany

Publications

  1. ncbi request reprint Strategic alliance management: lessons learned from the Bayer-Millennium collaboration
    Karl Ziegelbauer
    Bayer HealthCare AG, 42096 Wuppertal, Germany
    Drug Discov Today 9:864-8. 2004
  2. pmc A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity
    Karl Ziegelbauer
    Bayer Yakuhin, Ltd, Research Center Kyoto, Kyoto, Japan
    Br J Pharmacol 145:178-92. 2005
  3. pmc New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity
    Dieter Beyer
    Department of Anti infectives, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Antimicrob Agents Chemother 48:525-32. 2004
  4. pmc Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme
    Alexander Kuhl
    Bayer HealthCare AG, Pharma Research EU, D 42096 Wuppertal, Germany
    Antimicrob Agents Chemother 49:987-95. 2005
  5. pmc Novel whole-cell antibiotic biosensors for compound discovery
    Andreas Urban
    Pharma Research and Development, Discovery Europe, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Appl Environ Microbiol 73:6436-43. 2007
  6. ncbi request reprint Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity
    Christoph Freiberg
    Institute of Anti infectives Research, Institute of Chemistry Research, and Institute of Cardiovascular Research, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    J Biol Chem 279:26066-73. 2004
  7. doi request reprint Product-related research: how research can contribute to successful life-cycle management
    Peter Sandner
    Bayer HealthCare AG, Global Drug Discovery, Germany
    Drug Discov Today 13:457-63. 2008
  8. ncbi request reprint Genomics: success or failure to deliver drug targets?
    Ulrich Ak Betz
    Bayer HealthCare AG, Pharma Research and Development, Wuppertal, Germany
    Curr Opin Chem Biol 9:387-91. 2005
  9. ncbi request reprint Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors
    Noriyuki Yamamoto
    Research Center Kyoto, Bayer Yakuhin, Ltd, 6 5 1 3, Kunimidai, Kizu cho, Soraku gun, Kyoto 619 0216, Japan
    Anal Biochem 315:256-61. 2003
  10. pmc Prediction of mechanisms of action of antibacterial compounds by gene expression profiling
    Bernd Hutter
    GPC Biotech AG, Microbiology, Munich, Germany
    Antimicrob Agents Chemother 48:2838-44. 2004

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Strategic alliance management: lessons learned from the Bayer-Millennium collaboration
    Karl Ziegelbauer
    Bayer HealthCare AG, 42096 Wuppertal, Germany
    Drug Discov Today 9:864-8. 2004
  2. pmc A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity
    Karl Ziegelbauer
    Bayer Yakuhin, Ltd, Research Center Kyoto, Kyoto, Japan
    Br J Pharmacol 145:178-92. 2005
    ..10 These data suggest that IKK-beta inhibitors offer an effective therapeutic approach for inhibiting chronic pulmonary inflammation...
  3. pmc New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity
    Dieter Beyer
    Department of Anti infectives, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Antimicrob Agents Chemother 48:525-32. 2004
    ..pneumoniae sepsis model in rats. Treatment with the phenyl-thiazolylurea-sulfonamides reduced the bacterial titer in various organs by up to 3 log units, supporting the potential value of Phe-RS as a target in antibacterial therapy...
  4. pmc Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme
    Alexander Kuhl
    Bayer HealthCare AG, Pharma Research EU, D 42096 Wuppertal, Germany
    Antimicrob Agents Chemother 49:987-95. 2005
    ....
  5. pmc Novel whole-cell antibiotic biosensors for compound discovery
    Andreas Urban
    Pharma Research and Development, Discovery Europe, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    Appl Environ Microbiol 73:6436-43. 2007
    ..For instance, we show that the mechanistically underexplored antibiotic ferrimycin A1 selectively inhibits protein biosynthesis...
  6. ncbi request reprint Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity
    Christoph Freiberg
    Institute of Anti infectives Research, Institute of Chemistry Research, and Institute of Cardiovascular Research, Pharma Research, Bayer HealthCare AG, D 42096 Wuppertal, Germany
    J Biol Chem 279:26066-73. 2004
    ....
  7. doi request reprint Product-related research: how research can contribute to successful life-cycle management
    Peter Sandner
    Bayer HealthCare AG, Global Drug Discovery, Germany
    Drug Discov Today 13:457-63. 2008
    ..In this communication, we review how research organizations can contribute to successful life-cycle management strategies using phosphodiesterase 5 inhibitors as an example...
  8. ncbi request reprint Genomics: success or failure to deliver drug targets?
    Ulrich Ak Betz
    Bayer HealthCare AG, Pharma Research and Development, Wuppertal, Germany
    Curr Opin Chem Biol 9:387-91. 2005
    ....
  9. ncbi request reprint Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors
    Noriyuki Yamamoto
    Research Center Kyoto, Bayer Yakuhin, Ltd, 6 5 1 3, Kunimidai, Kizu cho, Soraku gun, Kyoto 619 0216, Japan
    Anal Biochem 315:256-61. 2003
    ..These data suggest that this assay is useful to screen Syk kinase inhibitors in HTS...
  10. pmc Prediction of mechanisms of action of antibacterial compounds by gene expression profiling
    Bernd Hutter
    GPC Biotech AG, Microbiology, Munich, Germany
    Antimicrob Agents Chemother 48:2838-44. 2004
    ..A database of this kind may facilitate the prioritization of novel antibacterial entities in drug discovery programs. Potential applications and limitations are discussed...
  11. ncbi request reprint Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones
    Heike Brötz-Oesterhelt
    Department of Anti infectives, Bayer AG, Bayer Health Care, Pharma Research, Aprather Weg 18a, D 42096 Wuppertal, Germany
    J Biol Chem 278:39435-42. 2003
    ....
  12. doi request reprint KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment
    Margarete Schön
    Department of Dermatology and Venereology, University Medical Center Gottingen, von Siebold Str 3, 37075 Gottingen, Germany
    J Natl Cancer Inst 100:862-75. 2008
    ..NF-kappaB is regulated by inhibitory kappaB (IkappaB) proteins, which are in turn phosphorylated by the IkappaB kinase (IKK) complex...
  13. pmc Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery
    Hans Peter Fischer
    Genedata AG, Postfach 254, CH 4016, Basel, Switzerland
    Genome Res 14:90-8. 2004
    ..In a proof-of-principle experiment, this assay was shown to enable screening for new small-molecule inhibitors of bacterial growth...
  14. doi request reprint IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells
    Elizabeth A Duncan
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    Mol Cancer Ther 7:391-7. 2008
    ..These data indicate that blockage of BCR-ABL-induced NF-kappaB activation via IkappaB kinase beta inhibition represents a potential new approach for treatment of Imatinib- or Dasatinib-resistant forms of chronic myelogenous leukemia...